Precision Biosciences (DTIL) Receivables - Net (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Receivables - Net of $4.0 million for Q1 2026, up 99900.0% year-over-year from N/an in Q1 2025, and up 99900.0% quarter-over-quarter from $4000.0 in Q3 2025.
Precision Biosciences (DTIL) Receivables - Net (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Receivables - Net for 9 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 99900.0% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 99900.0% YoY), while the FY2024 annual figure was $229000.0, down 74.58% from the prior year.
- Receivables - Net improved to $4.0 million in Q1 2026 per DTIL's latest filing, from $4000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $50.5 million in Q2 2022 and bottomed at $4000.0 in Q1 2025.
- Historically, Receivables - Net has averaged $4.2 million across 5 years, with a median of $652000.0 in 2023.
- Annual changes were most pronounced in 2025 — Receivables - Net tumbled 98.97% — and 2026, when it surged 99900.0%.
- Precision Biosciences' Receivables - Net stood at $720000.0 in 2022, then increased by 25.14% to $901000.0 in 2023, then plunged by 74.58% to $229000.0 in 2024, then tumbled by 98.25% to $4000.0 in 2025, then soared by 99900.0% to $4.0 million in 2026.
- Business Quant data shows DTIL's Receivables - Net at $4.0 million in Q1 2026, $4000.0 in Q3 2025, and $4000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Sep 30, 2025 | 4,000.00 |
| Sep 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 229,000.00 |
| Dec 31, 2024 | 229,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Sep 30, 2024 | 188,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Jun 30, 2024 | 207,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Dec 31, 2023 | 901,000.00 |
| Dec 31, 2023 | 901,000.00 |
| Sep 30, 2023 | 3.51 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 652,000.00 |
| Jun 30, 2023 | 652,000.00 |